KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Operating Expenses (2018 - 2025)

Historic Operating Expenses for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to $97.3 million.

  • Esperion Therapeutics' Operating Expenses rose 4376.42% to $97.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $333.2 million, marking a year-over-year increase of 1942.18%. This contributed to the annual value of $277.9 million for FY2024, which is 221.22% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Operating Expenses of $97.3 million as of Q3 2025, which was up 4376.42% from $75.3 million recorded in Q2 2025.
  • Esperion Therapeutics' Operating Expenses' 5-year high stood at $97.3 million during Q3 2025, with a 5-year trough of $60.6 million in Q3 2022.
  • Its 5-year average for Operating Expenses is $72.1 million, with a median of $71.2 million in 2022.
  • As far as peak fluctuations go, Esperion Therapeutics' Operating Expenses crashed by 3248.64% in 2021, and later surged by 4376.42% in 2025.
  • Quarter analysis of 5 years shows Esperion Therapeutics' Operating Expenses stood at $71.0 million in 2021, then dropped by 13.65% to $61.3 million in 2022, then rose by 21.66% to $74.6 million in 2023, then decreased by 1.45% to $73.5 million in 2024, then surged by 32.28% to $97.3 million in 2025.
  • Its Operating Expenses was $97.3 million in Q3 2025, compared to $75.3 million in Q2 2025 and $87.1 million in Q1 2025.